Taken together, our findings demonstrate the potential inhibitory efficacy of TIZ for GBM in vitro and in vivo, and CDK1 activity inhibition-induced TIZ-associated G2/M cell cycle arrest is the underlying molecular mechanism. The gene discussed is CDK1; the disease is glioblastoma.